Alimera Sciences Inc

Alimera Sciences — Q1 2017 Earnings Presentation

22 slides from Alimera Sciences's earnings presentation, May 9, 2017

  1. Slide 1: First Quarter 2017 Results Conference Call

    First Quarter 2017 Results Conference Call Tuesday, May 9, 2017 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for further growth in 2017 for ILUVIEN. Such forward-looking statements are based on current expec

  3. Slide 3: 1Q 2017 Highlights

    3 1Q 2017 Highlights Revenue Growth 1Q17 $6.6M 1Q16 $5.8M +14%• 32% growth in Q1 2017 global end unit demand • Reduced cost structure we believe positions us to achieve positive cash flow from operations later this year • Significant real world data and experience being presented in the U.S. at ARVO

  4. Slide 4: Real World Data

    4 Real World Data © 2017 Alimera Sciences, Inc., All Rights Reserved ARVO USER Study 27 Presentations related to ILUVIEN in May PALADIN Study 152 Patients; 186 Eyes 130 Patients; 160 Eyes

  5. Slide 5: International Expansion

    5 International Expansion © 2017 Alimera Sciences, Inc., All Rights Reserved We expect that ILUVIEN will be available for the first time in the following countries in 2017 • Italy • Spain • Austria • Ireland

  6. Slide 6: Financial Overview

    Financial Overview Rick Eiswirth, President & CFO

  7. Slide 7: Global Revenue and End User Unit Demand

    © 2017 Alimera Sciences, All Rights Reserved 7 1Q16 1Q17 $6.6M $5.8M +14% Global Revenue 1Q16 1Q17 +32% Global End User Unit Demand 1Q16 1Q17 $4.4M $4.1M +7% U.S. Revenue 1Q16 1Q17 $2.2M $1.7M +29% International Revenue

  8. Slide 8: Operating Expenses, Operating Loss and Adjusted EBITDA Loss

    8© 2017 Alimera Sciences, Inc., All Rights Reserved 1Q16 1Q17 $11.5M $14.2M 19% Operating Expenses 1Q16 1Q17 $5.5M $8.8M 38% GAAP Operating Loss 1Q16 1Q17 $3.7M $9.4M 61% Adj. EBITDA Loss* *Please see reconciliation to GAAP equivalent on slide 21 of this presentation 1Q16 1Q17 $9.7M $12.2M 20% Adj.

  9. Slide 9: Select Balance Sheet Data

    9 Select Balance Sheet Data ($000’s) As of March 31, 2017 (Unaudited) As of December 31, 2016 Cash & Cash Equivalents $26,737 $30,979 Total Current Assets $40,450 $47,402 Total Assets $62,590 $70,229 Total Current Liabilities $6,777 $9,123 Total Stockholder’s Equity $20,066 $25,586 © 2017 Alimera Sc

  10. Slide 10: The ILUVIEN Technology

    Dr. Christopher Riemann Volunteer Professor, University of Cincinnati, Department of Ophthalmology and Director, Vitreoretinal Fellowship, Member, Board of Directors, Cincinnati Eye Institute The ILUVIEN® Technology

  11. Slide 11: DME Treatments: Steroids

    11 DME Treatments © 2017 Alimera Sciences, Inc., All Rights Reserved Steroids have a significant role in treating DME • DME is Multifactorial, corticosteroids are often needed for treatment • Prior to the advent of anti-VEGF’s, we used crude steroids Kenalog & PF Kenalog • Great efficacy • Side effe

  12. Slide 12: DME Treatments: Anti-VEGF Drugs Are Not a Magic Bullet

    12 DME Treatments © 2017 Alimera Sciences, Inc., All Rights Reserved Anti-VEGF Drugs are NOT a “magic bullet” for DME • Good efficacy – not great • DME is not AMD • 37-64% DME non-responder rate to Anti-VEGF • Side effects remain a challenge • Elevated IOP with more injections • Cataract and complic

  13. Slide 13: The U.S. Indication Mitigates the Risk of Elevated IOP Requiring Surgery

    13 The U.S. Indication Mitigates the Risk of Elevated IOP Requiring Surgery © 2017 Alimera Sciences, Inc., All Rights Reserved “ILUVIEN contains a corticosteroid and is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids

  14. Slide 14: IOP-Related Events in the FAME Phase 3 Study

    14 IOP-Related Events Over 36 Months For All ILUVIEN Treated Subjects in the FAME Phase 3 Study Were Consistent with the Steroid Class © 2017 Alimera Sciences, Inc., All Rights Reserved ILUVIEN (N = 375) n (%) Control (N = 185) n (%) IOP elevation ≥ 10 mm Hg from baseline 127 (34) 18 (10) IOP elevat

  15. Slide 15: IOP Response to a Prior Steroid Predicts Response to ILUVIEN

    15 The FDA Determined That IOP Response to a Prior Steroid is a Predictor of IOP Response to ILUVIEN Based on a Subgroup Analysis From FAME © 2017 Alimera Sciences, Inc., All Rights Reserved Known Prior Ocular Steroid Injection in Patients Treated With 0.2 µg/d Fac (ILUVIEN) n = 72* No Known Prior O

  16. Slide 16: The U.S. Indication Mitigates the Risk of Elevated IOP Requiring Surgery

    16 The U.S. Indication Mitigates the Risk of Elevated IOP Requiring Surgery © 2017 Alimera Sciences, Inc., All Rights Reserved “ILUVIEN contains a corticosteroid and is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids

  17. Slide 17: ILUVIEN Steroid Is Highly Lipophilic, Penetrating the Retina

    17 The Steroid Released by ILUVIEN is Highly Lipophilic – Which Leads to Excellent Penetration of the Retina © 2017 Alimera Sciences, Inc., All Rights Reserved Water Solubility of Ocular Steroids at 25°C mg/ml Multiple Dexamethasone 101 1,030 Fluocinolone Acetonide 0.05472 5.6 1 O’Neil, M.J. (ed.).

  18. Slide 18: FAc Concentration Remains Low Throughout the Life of the Implant

    18 The FAc Concentration is Low and Remains Low in ILUVIEN Throughout the Life of the Implant © 2017 Alimera Sciences, Inc., All Rights Reserved D ex am et ha so ne C on ce nt ra tio n (n g/ m L or n g/ g) Days 1000000 100000 10000 1000 100 10 1 0.1 0.01 0.001 0.0001 0 60 120 180 240 Vitreous (impla

  19. Slide 19: Why I Use ILUVIEN

    19 Why I Use ILUVIEN: © 2017 Alimera Sciences, Inc., All Rights Reserved ILUVIEN represents “next generation steroid” technology” and is a game changer • Not like the steroids of the past… • Low amount of steroid delivered consistently and continuously • Continuous microdosing • Near zero order kine

  20. Slide 20: Closing Remarks

    Closing Remarks Dan Myers, CEO

  21. Slide 21: Non-GAAP Financial Information

    21 Non-GAAP Financial Information © 2017 Alimera Sciences, Inc., All Rights Reserved Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This

  22. Slide 22: First Quarter 2017 Results Conference Call

    First Quarter 2017 Results Conference Call Tuesday, May 9, 2017

Alimera Sciences — Q1 2017 Earnings Presentation on 6ix